Purpose: Our study consisted in monitoring the viral load and CD4 count of people living with HIV/AIDS under antiretroviral trait treatment (ART) who came for biological follow-up at the Point G Hospital biomedical laboratory, then to describe the sociodemographic and clinical characteristics of these patients, and finally to establish a correlation between the viral load and the sociodemographic and clinical characteristics of these cases. Methods: It was a cross-sectional study with prospective recruitment from January to December 2024, conducted at the Point G Hospital biomedical laboratory. The study population included people living with HIV/AIDS who presented to the laboratory for a biological follow-up testing for ART. In particular, measurement of HIV viral load and CD4 count. Data were collected using individual patient data collection designed for the needs of the study. Results: The study involved 82 patients. The survey revealed that 69.5% of the patients were women. The average age of the participants was 40.55 years, and 81.7% of them lived in Bamako. Housewives represented 46.3% of the participant. HIV-1 was the most common type of virus (98.8%), and 60.9% of the patients were classified as stage 1 according to the WHO. The patients (96.3%) were on first-line treatment, primarily the TDF-3TC-DTG regimen (62.2%). Regarding viral load, 56.1% of patients had a viral load greater than 1000 copies/ml at inclusion, but at 6 months, 63.4% of patients had returned to a viral load below 40 copies/ml, and at 12 months, this number had risen to 86.6%. At inclusion, 24.4% of patients had a CD4 count below 500 cells/mm3. There was no significant link between the duration of ART and viral load at 6 months, but a significant link was observed at 12 months. Additionally, 81.7% of patients had good adherence to treatment, with medication errors and illnesses being the main causes of non-adherence (40% each). Conclusion: This study showed that the majority of our patients responded favourably to ART.
References
[1]
Cai, Y., Karaca-Griffin, S., Chen, J., Tian, S., Fredette, N., Linton, C.E., et al. (2017) Antigenicity-Defined Conformations of an Extremely Neutralization-Resistant HIV-1 Envelope Spike. Proceedings of the National Academy of Sciences of the United States of America, 114, 4477-4482. https://doi.org/10.1073/pnas.1700634114
[2]
Chiodi, F., Bj？rling, E., Samuelsson, A. and Norrby, E. (1993) Antigenic and Immunogenic Sites of HIV-2 Glycoproteins. In: Norrby, E., Ed., Chemical Immunology and Allergy, KARGER, 61-77. https://doi.org/10.1159/000319156
[3]
Esbj？rnsson, J., Jansson, M., Jespersen, S., M？nsson, F., H？nge, B.L., Lindman, J., et al. (2019) HIV-2 as a Model to Identify a Functional HIV Cure. AIDS Research and Therapy, 16, Article No. 24. https://doi.org/10.1186/s12981-019-0239-x
[4]
Nyamweya, S., Hegedus, A., Jaye, A., Rowland-Jones, S., Flanagan, K.L. and Macallan, D.C. (2013) Comparing HIV-1 and HIV-2 Infection: Lessons for Viral Immunopathogenesis. Reviews in Medical Virology, 23, 221-240. https://doi.org/10.1002/rmv.1739
[5]
Visseaux, B., Le Hingrat, Q., Damond, F., Charpentier, C. and Descamps, D. (2019) Physiopathology of HIV-2 Infection. Virologie, 23, 277-291. https://doi.org/10.1684/vir.2019.0789
[6]
Shaw, G.M. and Hunter, E. (2012) HIV Transmission. Cold Spring Harbor Perspectives in Medicine, 2, a006965. https://doi.org/10.1101/cshperspect.a006965
[7]
Shubber, Z., Mishra, S., Vesga, J.F. and Boily, M. (2014) The HIV Modes of Transmission Model: A Systematic Review of Its Findings and Adherence to Guidelines. Journal of the International AIDS Society, 17, Article ID: 18928. https://doi.org/10.7448/ias.17.1.18928
[8]
Volmink, J. and Marais, B. (2008) HIV: Mother-to-Child Transmission. BMJ Clinical Evidence, 2008, 0909.
[9]
UNAIDS (2023) Global HIV Statistics—Fact Sheet 2023. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf
[10]
Cellule de Planification et de Statistique (CPS/SSDSPF), Institut National de La Statistique (INSTAT/MPATP) and Internationa I-SeI (2013) Enquête Démographique et de Santé Au Mali 2012-2013. CPS, INSTAT, INFO-STAT et ICF International. https://dhsprogram.com/pubs/pdf/PR33/PR33
[11]
Lahuerta, M., Patnaik, P., Ballo, T., Telly, N., Knox, J., Traore, B., et al. (2017) HIV Prevalence and Related Risk Factors in Men Who Have Sex with Men in Bamako, Mali: Findings from a Bio-Behavioral Survey Using Respondent-Driven Sampling. AIDS and Behavior, 22, 2079-2088. https://doi.org/10.1007/s10461-017-1793-7
[12]
Traoré, B. (2023) Evaluation clinique et biologique des personnes vivant avec le VIH sous trithérapie antirétrovirale depuis six mois a l’USAC du centre de sante de référence de la commune I du district de Bamako. Master’s Thesis, Université des Sciences, des Techniques et des Technologies de Bamako.
[13]
Angira, F., Akoth, B., Omolo, P., Opollo, V., Bornheimer, S., Judge, K., et al. (2016) Clinical Evaluation of the BD Facspresto？ Near-Patient CD4 Counter in Kenya. PLOS ONE, 11, e0157939. https://doi.org/10.1371/journal.pone.0157939
[14]
Sukapirom, K., Matchua, S., Thepthai, C., Srimark, N., Khowawisetsut, L. and Pattanapanyasat, K. (2022) Performance Evaluation of BD Facsprestotm Near-Patient CD4 Counter for Monitoring Antiretroviral Therapy in HIV-Infected Individuals in Primary Healthcare Clinics in Thailand. Diagnostics, 12, Article 382. https://doi.org/10.3390/diagnostics12020382
[15]
Mouna, L., Pallier, C., Proust, S., Prégermain, C. and Roque-Afonso, A. (2020) Comparison of the Abbott Alinity M and M2000 Assays for the Quantification of HIV-1, HCV and HBV in Clinical Samples. Journal of Clinical Virology, 126, Article ID: 104331. https://doi.org/10.1016/j.jcv.2020.104331
[16]
Gazzard, B. (2008) British HIV Association Guidelines for the Treatment of HIV-1-Infected Adults with Antiretroviral Therapy 2008. HIV Medicine, 9, 563-608. https://doi.org/10.1111/j.1468-1293.2008.00636.x
[17]
Melku, M., Abebe, G., Teketel, A., Asrie, F., Yalew, A., Biadgo, B., et al. (2020) Immunological Status and Virological Suppression among HIV-Infected Adults on Highly Active Antiretroviral Therapy. Environmental Health and Preventive Medicine, 25, Article No. 43. https://doi.org/10.1186/s12199-020-00881-6
[18]
Demas, Z., Gebremariam, A., Kebede, A. and Ayele, L. (2022) Adherence to Antiretroviral Treatment and Associated Factors among Seropositive People Received Treatment in Jimma Town Public Health Facilities, Ethiopia. Journal of the International Association of Providers of AIDS Care (JIAPAC), 21, 4. https://doi.org/10.1177/23259582221121096
[19]
Jacques, Z., Marguerite, P.E.M., Firmin, K.N. and Issouf, Y.I. (2021) Le traitement antiretrovial des patients et leur pronostic à l’h？pital de jour du CHU Sour？ Sanou de Bobo-Dioulasso de 2014 à 2017 The Antiretrovial Treatment of Patients and their Prognosis at the Day hospital of the CHU Sour？ Sanou in Bobo-Dioulasso from 2014 to 2017. Revue Internationaledes Sciences Médicalesd’Abidjan, 7, 4.
[20]
Jacomet, C., Cormerais, L., Peyrol, F., Guiguet, M., Simon, A., Berland, P., et al. (2014) Bulletin épidémiologique Hebdomadaire. 422-428. https://mediatheque.lecrips.net/index.php
[21]
Mouhari-Toure, A., et al. (2011) [Biological Profile of Adult Patients Infected with HIV at Initiation of Antiretroviral Therapy in Togo]. Médecineet Maladies Infectieuses, 41, 229-234.
[22]
Potchoo, Y., Tchamdja, K., Balogou, A., Pitche, V.P., Guissou, I.P. and Kassang, E.K. (2010) Knowledge and Adherence to Antiretroviral Therapy among Adult People Living with HIV/AIDS Treated in the Health Care Centers of the Association “Espoir Vie Togo” in Togo, West Africa. BMC Clinical Pharmacology, 10, Article No. 11. https://doi.org/10.1186/1472-6904-10-11
[23]
Sissoko, G. (2024) Suivi biologique des personnes vivant avec le VIH/SIDA sous traitement ARV au CSRef de la commune V du district de Bamako. Ph.D. Thesis, USTTB.
[24]
Lewden, C., Drabo, Y.J., Zannou, D.M., Maiga, M.Y., Minta, D.K., Sow, P.S., et al. (2014) Disease Patterns and Causes of Death of Hospitalized HIV-Positive Adults in West Africa: A Multicountry Survey in the Antiretroviral Treatment Era. Journal of the International AIDS Society, 17, Article ID: 18797. https://doi.org/10.7448/ias.17.1.18797
[25]
David, W.S., Nkenge Masudi, B., Amani Lubunga, E., Imanya Cubaka, F., Abedi Zalufa, M., Bihehe Masemo, D., et al. (2023) Profil de la charge virale chez les personnes vivant avec le virus de l’immunodéficience humaine suivies au centre de traitement ambulatoire de l’H？pital Général de Référence de Panzi: Etude transversale descriptive. Kivu Medical Journal, 1, 1-6. https://doi.org/10.64263/kmj.v1i2.7
[26]
Sall, H. (2023) Séroprévalence et Caractéristiques Immuno-Virologiques du VHB chez des Personnes Vivant avec le VIH au CESAC de Bamako. Ph.D. Thesis, Université des Sciences, des Techniques et des Technologies de Bamako.
[27]
Ghys, P.D., Voetsch, A.C., Justman, J.E., Patel, H., DeVos, J.R., Brown, K., et al. (2026) HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022. AIDS, 40, 982-991. https://doi.org/10.1097/qad.0000000000004471
[28]
Calmy, A., et al. (2020) Dolutegravir-Based and Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-1 Infection (NAMSAL): Week 96 Results from a Two-Group, Multicentre, Randomised, Open Label, Phase 3 Non-Inferiority Trial in Cameroon. Lancet HIV, 7, e677-e687.
[29]
Achieng, L., Musangi, H., Ong’uti, S., Ombegoh, E., Bryant, L., Mwiindi, J., et al. (2012) An Observational Cohort Comparison of Facilitators of Retention in Care and Adherence to Anti-Eetroviral Therapy at an HIV Treatment Center in Kenya. PLOS ONE, 7, e32727. https://doi.org/10.1371/journal.pone.0032727
[30]
Dou, Y., Liao, G., Lu, R., Su, L., Lan, K., Meng, Z., et al. (2024) DTG + 3TC Dual Therapy for the Treatment Na？ve Patients with Viral Load Exceeding 500,000 Copies/mL: A Retrospective Study. BMC Infectious Diseases, 24, Article No. 720. https://doi.org/10.1186/s12879-024-09624-2
[31]
Sar？gül Y？ld？r？m, F., Candevir, A., Akhan, S., Kaya, S., ？abalak, M., Ers？z, G., et al. (2023) Comparison of Immunological and Virological Recovery with Rapid, Early, and Late Start of Antiretroviral Treatment in Naive Plwh: Real-World Data. International Journal of General Medicine, 16, 1867-1877. https://doi.org/10.2147/ijgm.s393370
[32]
Lozes, E., Ahoussinou, C., Agassounon Tchibozo Djikpo, M., Dahouegnon, E., Ahossouhe, N., Acoty, A., et al. (2012) Variabilité du taux des lymphocytes CD4 et de la charge virale chez les personnes vivant avec le VIH sous traitement antiretroviral: Cas de l’hopital saint Jean De Dieu de Tanguieta (Benin). International Journal of Biological and Chemical Sciences, 6, 650-656. https://doi.org/10.4314/ijbcs.v6i2.9
